Jefferies positive on CSL in near-term, sees growth in plasma industry

BUZZ – Jefferies positive on CSL in near – term, sees growth in plasma industry

01 Feb 2021 14:48

• * Jefferies is positive on drugmaker CSL in near-term, as it foresees growth in plasma industry and notes co's margins in industry about one-third higher than peers
• * Says only 20% of total potential patients in U.S and EU are receiving plasma treatment for most penetrated of base and specialty products, implying CSL and industry can continue to grow strongly
• * Jefferies also says co's Q2 projected earnings in U.S bodes well for its H1 FY21 margin
• * Brokerage uses data from IQVIA Health, a healthcare information and technology firm, which says that in 2QFY21, U.S. plasma product revenue increased by 9.5%, with high-margin specialty products up 18%
• * Notes U.S. flu vaccine revenue decreased by 7%, according to IQVIA, but higher-margin Fluad Quad sales now comprise about 40% of total flu vaccine sales - which may lead to higher margins in first-half
• * Sees 9% growth for CSL's high margin specialty product franchise in FY21

(Reporting by Arundhati Dutta in Bengaluru) (([email protected]

© 2021 Thomson Reuters. Click for Restrictions.